Patents by Inventor Caroline DIVEU-SADER

Caroline DIVEU-SADER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOGENIC COMPOSITION COMPRISING CYAA-DERIVED POLYPEPTIDE PROMOTING A TH1/TH17-ORIENTED IMMUNE RESPONSE
    Publication number: 20230165950
    Abstract: The invention relates to the use of a polypeptide derived from the adenylate cyclase of a Bordetella sp. (CyaA-derived polypeptide) by deletion of a segment of at least 93 amino acid residues, in particular a polypeptide derived from CyaA of Bordetella pertussis, as an immunomodifying antigen of the TH1/TH17-oriented immune response in an immunogenic composition. The invention relates to a vaccine candidate comprising such CyaA-derived polypeptide, either in an acellular immunogenic composition for active immunization against a condition causally related to the infection of a host by Bordetella sp. or in a combination composition encompassing said acellular immunogenic composition.
    Type: Application
    Filed: July 26, 2022
    Publication date: June 1, 2023
    Inventors: Rémi PALMANTIER, Yolande MISSERI, Caroline DIVEU-SADER, Sunil GAIROLA, Manish GAUTAM, Harish RAO, Umesh SHALIGRAM
  • IMMUNOGENIC COMPOSITION COMPRISING CYAA-DERIVED POLYPEPTIDE PROMOTING A TH1/TH17-ORIENTED IMMUNE RESPONSE
    Publication number: 20190307875
    Abstract: The invention relates to the use of a polypeptide derived from the adenylate cyclase of a Bordetella sp. (CyaA-derived polypeptide) by deletion of a segment of at least 93 amino acid residues, in particular a polypeptide derived from CyaA of Bordetella pertussis, as an immunomodifying antigen of the TH1/TH17-oriented immune response in an immunogenic composition. The invention relates to a vaccine candidate comprising such CyaA-derived polypeptide, either in an acellular immunogenic composition for active immunization against a condition causally related to the infection of a host by Bordetella sp. or in a combination composition encompassing said acellular immunogenic composition.
    Type: Application
    Filed: December 22, 2017
    Publication date: October 10, 2019
    Applicants: GENKYOTEX, SERUM INSTITUTE OF INDIA PRIVATE LIMITED
    Inventors: Rémi PALMANTIER, Yolande MISSERI, Caroline DIVEU-SADER, Sunil GAIROLA, Manish GAUTAM, Harish RAO, Umesh SHALIGRAM